{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:24:30Z","timestamp":1791415470164,"version":"4.3.3"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"am","delay-in-days":285,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"NIAID DMID","doi-asserted-by":"publisher","award":["75N93019C00058"],"award-info":[{"award-number":["75N93019C00058"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"NIAID DMID","doi-asserted-by":"publisher","award":["HHSN272201500008C"],"award-info":[{"award-number":["HHSN272201500008C"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"NIAID DMID","doi-asserted-by":"publisher","award":["SP00013673-01"],"award-info":[{"award-number":["SP00013673-01"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.coviro.2021.06.003","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T07:28:43Z","timestamp":1624001323000},"page":"17-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"special_numbering":"C","title":["Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19"],"prefix":"10.1016","volume":"50","author":[{"given":"George R","family":"Painter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G","family":"Natchus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6835-3473","authenticated-orcid":false,"given":"Oren","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy P","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2021.06.003_bib0005","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2021.06.003_bib0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2021.06.003_bib0015","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1473-3099(20)30200-0","article-title":"Clinical and virological data of the first cases of COVID-19 in Europe: a case series","volume":"20","author":"Lescure","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2021.06.003_bib0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2021.06.003_bib0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2021.06.003_bib0030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2021.06.003_sbref0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coviro.2021.06.003_bib0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.trsl.2019.12.002","article-title":"Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model","volume":"218","author":"Toots","year":"2020","journal-title":"Transl Res"},{"key":"10.1016\/j.coviro.2021.06.003_sbref0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2021.06.003_sbref0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2021.06.003_bib0055","doi-asserted-by":"crossref","first-page":"e01348","DOI":"10.1128\/JVI.01348-19","article-title":"Small-molecule antiviral \u03b2-D-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2021.06.003_bib0060","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2021.06.003_bib0065","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/0300985810372508","article-title":"REVIEW PAPER: pathology of animal models of alphavirus encephalitis","volume":"47","author":"Steele","year":"2010","journal-title":"Vet Pathol"},{"key":"10.1016\/j.coviro.2021.06.003_bib0070","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/bsp.2009.0032","article-title":"Alphavirus antiviral drug development: scientific gap analysis and prospective research areas","volume":"7","author":"Reichert","year":"2009","journal-title":"Biosecur Bioterror"},{"key":"10.1016\/j.coviro.2021.06.003_bib0075","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.vetmic.2009.08.023","article-title":"Encephalitic alphaviruses","volume":"140","author":"Zacks","year":"2010","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.coviro.2021.06.003_bib0080","series-title":"Textbooks of Military Medicine\u2014Medical Aspects of Biological Warfare","first-page":"241","article-title":"Alphavirus encephalitides","author":"Steele","year":"2007"},{"key":"10.1016\/j.coviro.2021.06.003_bib0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12866-017-1080-9","article-title":"Improved detection of genus-specific Alphavirus using a generic TaqMan\u00ae assay","volume":"17","author":"Giry","year":"2017","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.coviro.2021.06.003_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005693","article-title":"Evolution and spread of Venezuelan equine encephalitis complex alphavirus in the Americas","volume":"11","author":"Forrester","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2021.06.003_bib0095","first-page":"164","article-title":"Venezuelan equine encephalitis in BALB\/c mice: kinetic analysis of central nervous system infection following aerosol or subcutaneous inoculation","volume":"120","author":"Vogel","year":"1996","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.coviro.2021.06.003_bib0100","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1007\/BF01323243","article-title":"Spread of Venezuelan equine encephalitis virus in mice olfactory tract","volume":"140","author":"Ryzhikov","year":"1995","journal-title":"Arch Virol"},{"key":"10.1016\/j.coviro.2021.06.003_bib0105","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3201\/eid2212.160123","article-title":"Assessing the epidemic potential of RNA and DNA viruses","volume":"22","author":"Woolhouse","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2021.06.003_bib0110","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2018.17","article-title":"Epidemiological characteristics of human-infective RNA viruses","volume":"5","author":"Woolhouse","year":"2018","journal-title":"Sci Data"},{"key":"10.1016\/j.coviro.2021.06.003_bib0115","doi-asserted-by":"crossref","first-page":"E4005","DOI":"10.1073\/pnas.1602591113","article-title":"Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation","volume":"113","author":"Shu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2021.06.003_bib0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-2836(02)01033-1","article-title":"The palm subdomain-based active site is internally permuted in viral RNA-dependent RNA polymerases of an ancient lineage","volume":"324","author":"Gorbalenya","year":"2002","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coviro.2021.06.003_bib0125","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/313762a0","article-title":"Structure of large fragment of Escherichia coli DNA polymerase I complexed with dTMP","volume":"313","author":"Ollis","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2021.06.003_bib0130","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coviro.2021.06.003_bib0135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coviro.2021.06.003_bib0140","doi-asserted-by":"crossref","DOI":"10.1177\/2040206618764483","article-title":"Nucleosides for the treatment of respiratory RNA virus infections","volume":"26","author":"Jordan","year":"2018","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.coviro.2021.06.003_bib0145","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02395-16","article-title":"Characterization of \u03b2-d-N(4)-hydroxycytidine as a novel inhibitor of chikungunya virus","volume":"61","author":"Ehteshami","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2021.06.003_bib0150","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.3390\/v7122934","article-title":"Identification of a new ribonucleoside inhibitor of Ebola virus replication","volume":"7","author":"Reynard","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2021.06.003_bib0155","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3851\/IMP2229","article-title":"Antiviral activity of nucleoside analogues against norovirus","volume":"17","author":"Costantini","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.coviro.2021.06.003_bib0160","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1128\/AAC.01598-05","article-title":"Inhibition of human coronavirus NL63 infection at early stages of the replication cycle","volume":"50","author":"Pyrc","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2021.06.003_bib0165","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1135\/cccc20061099","article-title":"New N4-hydroxycytidine derivatives: synthesis and antiviral activity","volume":"71","author":"Ivanov","year":"2006","journal-title":"Collect Czechoslov Chem Commun"},{"key":"10.1016\/j.coviro.2021.06.003_bib0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/095632020401500102","article-title":"Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine","volume":"15","author":"Barnard","year":"2004","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.coviro.2021.06.003_bib0175","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1128\/AAC.47.1.244-254.2003","article-title":"Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture","volume":"47","author":"Stuyver","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2021.06.003_sbref0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104597","article-title":"The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection","volume":"171","author":"Painter","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2021.06.003_bib0185","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.fct.2016.08.035","article-title":"The current limitations of in vitro genotoxicity testing and their relevance to the in vivo situation","volume":"106","author":"Nesslany","year":"2017","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.coviro.2021.06.003_bib0190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/mutage\/gey005","article-title":"A critical appraisal of the sensitivity of in vivo genotoxicity assays in detecting human carcinogens","volume":"33","author":"Zeller","year":"2018","journal-title":"Mutagenesis"},{"key":"10.1016\/j.coviro.2021.06.003_sbref0195","doi-asserted-by":"crossref","first-page":"e02428-20","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625721000663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625721000663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:04:59Z","timestamp":1761818699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625721000663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":39,"alternative-id":["S1879625721000663"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2021.06.003","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2021.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}